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PMH24
IMPROVEMENT OF FATIGUE IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER TREATED WITH VENLAFAXINE,
SERTRALINE, OR PLACEBO
Zhang HF, Khandker R
Wyeth Research, Collegeville, PA, USA
OBJECTIVE: This analysis was designed to compare improve-
ment in symptoms of fatigue in depressed patients treated 
with venlafaxine extended release (XR), sertraline, or placebo.
METHODS: Data were pooled from two identical ten-week,
multicenter, randomized, double-blind, placebo-controlled
studies of ﬂexible-dose venlafaxine XR (37.5–300mg/day) and
sertraline (50–200mg/day) in the treatment of DSM-IV major
depressive disorder (N = 1352). The Hamilton Rating Scale for
Depression scale (HAM-D) energy subscale (sum of items one,
seven, eight, and 14) and the Montgomery-Asberg Depression
Rating Scale (MADRS) lassitude item were used to assess fatigue
symptoms. Improvement was measured as reduction from base-
line score at week ten using ANCOVA method controlling for
center and baseline values. Overall trend of weekly scores during
treatment was measured using repeated measures mixed model.
The last-observation-carried-forward (LOCF) approach was
used to handle missing data. RESULTS: On the MADRS lassi-
tude item venlafaxine XR was associated with signiﬁcantly
greater reduction from baseline (P < 0.0001) and signiﬁcantly
better weekly trend (P < 0.0001) versus placebo. Venlafaxine XR
was also associated with signiﬁcantly greater reduction from
baseline on the HAM-D energy subscale (P = 0.0007) and better
overall weekly trend (P = 0.0003) relative to placebo. Sertra-
line/placebo differences were also statistically signiﬁcant. 
CONCLUSION: Venlafaxine XR and sertraline treatment were
associated with signiﬁcant improvement in fatigue symptoms in
depressed patients based on two independent measures.
PMH25
COST AND UTILIZATION DIFFERENCES AMONG CARDIAC
PATIENTS TREATED FOR DEPRESSION WITH ZOLOFT
VERSUS NO PHARMACEUTICAL TREATMENT
Bron MS1, Mark TL2, Orsini LS3
1Pﬁzer, New York, NY, USA; 2Medstat, Washington, DC, USA;
3MedStat, Inc, Cambridge, MA, USA
OBJECTIVE: To determine the differences in health care expen-
ditures among patients hospitalized with acute myocardial
infarction or unstable angina that were subsequently treated for
depression associated with their cardiac event with either ser-
taline or no antidepressant therapy. METHODS: Patients 45 or
older, 12 months of continuous enrollment, evidence of pre-
scription drug claims, a hospitalization for either acute myocar-
dial infarction (ICD-9-CM code 411.1x) or unstable angina
(410.00–410.92) and evidence of depression treatment (diagno-
sis or pharmaceutical) were identiﬁed in Medstat’s MarketScan
Databases. Claims incurred between January 1, 1999 and
December 31, 2003 were utilized. Patients without any antide-
pressant use 30 days prior or 60 days after their cardiac event
and receiving a diagnosis of depression in the 180 days before
or after their cardiac event comprised the diagnosis only group.
Patients with a 30 day clean period of any antidepressant prior
to their cardiac event and incurring a script for sertaline (but no
other antidepressant) in the 60 days after their cardiac event
comprised the sertaline group. Patients in the two groups were
matched using propensity score methods. RESULTS: A total 
of 257 patients in each group were identiﬁed. The mean total
per person expenditure for acute MI admission was signiﬁcantly
higher for diagnosis only patients ($3184) versus sertaline
patients ($1063) p = 0.0098. The mean total per person expen-
diture for psychiatric related outpatient visits was also higher in
the diagnosis only group: $326 versus $69 p < 0.0001. There
were no other signiﬁcant differences in expenditures. CON-
CLUSION: Patients treated for depression after a hospitalization
for a major coronary event who receive sertaline have fewer AMI
admissions and costs for AMI admissions as well as fewer psy-
chiatric related outpatient visits and related costs in the 24 weeks
following their initial cardiac event.
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COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE
TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TURKEY
Hemels ME1, Karamustafal oglu O2, Ozmen E3, Dilsad S4, Mene S3
1H. Lundbeck A/S, Paris, Ile de France, France; 2Etfal Hospital, Istanbul,
Sisli,Turkey; 3Lundbeck Ìlaç Ticaret Limited, Istanbul, Ìlaç,Turkey;
4Marmara University, Istanbul,Turkey
OBJECTIVES: To compare the cost-effectiveness of escitalopram
with generic citalopram and venlafaxine in the treatment of
Major Depressive Disorder (MDD) in Turkey. METHODS: A
decision analytic model with a six-month horizon was adapted
to the Turkish setting. All patients (aged ≥ 18 years) were treated
by a psychiatrist over a period of six months. Model inputs
included drug-speciﬁc probabilities from head-to-head trial data,
literature, and expert opinion. A national survey was conducted
among psychiatrists (n = 90; response rate = 96.7%) to obtain
patterns of clinical management, resource utilization and lost
productivity data (all weighted by practice size). The main
outcome measure was success [i.e., remission deﬁned as Mont-
gomery-Åsberg Depression Rating Scale (MADRS) score £12]
and costs (in US$ 2004) of treatment (i.e., costs of drugs and
medical care). The analysis was performed from the govern-
mental and societal perspectives. Human capital approach was
used to estimate the cost of lost productivity using the minimal
industrial wage in Turkey. RESULTS: Treatment with escitalo-
pram yielded lower expected costs and greater effectiveness com-
pared with citalopram. The expected success rate was higher for
escitalopram [63.2% (CI95 61.1%–65.3%)] compared with
generic citalopram [57.6% (CI95 55.3%–59.9%)]. From the
governmental perspective, total expected costs were US$297
(US$282–US$313) for escitalopram and US$305 (US$288–
US$322) for generic citalopram. From the societal perspective
the costs per patient were US$678 (US$653–US$705) for esci-
talopram and US$709 (US$682–US$736) for generic citalopram.
For venlafaxine, a similar success rate compared with escitalo-
pram but higher total costs were found from both the govern-
mental (i.e., 23.5%) and societal (i.e., 9.3%) perspectives.
Multivariate sensitivity analyses on unit costs and probabilities
demonstrated the robustness of the results. CONCLUSION:
Escitalopram is a cost-effective alternative compared to (generic)
citalopram and a cost saving alternative compared with ven-
lafaxine in the treatment of MDD in Turkey.
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COST-EFFECTIVENESS OF ESCITALOPRAM VS. VENLAFAXIN
XR IN THE TREATMENT OF MAJOR DEPRESSIVE 
DISORDER IN GERMANY
Kulp W1, Greiner W2, Schulenburg JM3
1University of Hannover, Hannover, Germany; 2University of
Hannover, Hannover, Germany; 3University of Hannover, Hannover,
Germany
OBJECTIVE: The treatment of Major Depressive Disorder
(MDD) represents a substantial ﬁnancial burden to modern
health care systems. The 12-month prevalence is estimated to be
12% in adult patients. Selective serotoninreuptake-inhibitors
(SSRI) such as Escitalopram and Venlafaxin XR play an impor-
y¢
